{
  "abstract": "Background: Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to <30 kg/m2 and adiposity-related complications have not been characterized. Adults with overweight and an adiposity-related complication are at substantial cardiometabolic risk, and obesity medications are recommended for this group.\n\nMethods: This was a post-hoc analysis of the ATTAIN-1 trial (NCT05869903), a phase 3, randomized, double-blind, placebo-controlled trial in which adults without diabetes and with obesity or overweight were randomized 3:3:3:4 to once-daily oral orforglipron 5.5, 9, or 17.2 mg or placebo for 72 weeks. The present analysis included the subset of randomized participants with BMI ≥27 to <30 kg/m2 and ≥1 adiposity-related complication. Endpoints included change from baseline to Week 72 the percent change in body weight, BMI, categorical weight-loss, waist circumference, lipids, patient-reported outcomes, and safety. Effect estimates are reported using efficacy and treatment-regimen estimands. Efficacy endpoints were also reported per sex subgroup.\n\nResults: This analysis included 260 participants (orforglipron 5.5 mg: 56; 9 mg: 64; 17.2 mg: 62; placebo: 78). At Week 72, orforglipron was associated with greater mean percent body weight reduction (17.2 mg: −13.5%) versus placebo (−0.3%) (nominal p < 0.001). Females experienced up to −18.8% mean body weight reduction and males up to −10.0%. Orforglipron was associated with improvements in waist circumference, triglycerides, and low-density lipoprotein cholesterol, as well as improvements in patient-reported outcomes. Safety profile was consistent with previous trials with predominantly mild-to-moderate gastrointestinal events.\n\nConclusion: In this post hoc analysis of ATTAIN-1, participants with BMI ≥27 to <30 kg/m2 and ≥1 adiposity-related complication, orforglipron was associated with improvements in anthropometric and cardiometabolic parameters, with a safety profile broadly consistent with the overall ATTAIN-1 trial (ClinicalTrials.gov identifier: NCT05869903).",
  "abstract_shown": true,
  "affiliations": [
    "Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX, USA",
    "School of Medicine, Faculty of Life & Health Sciences, Ulster University, UK",
    "Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Helmholtz Center Munich, Leipzig University and University of Leipzig Medical Center, Leipzig, Germany",
    "University of Leipzig Medical Center, Leipzig, Germany",
    "Eli Lilly and Company, Indianapolis, IN, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jaime P. Almandoz"
    },
    {
      "affs": [
        1
      ],
      "name": "Alexander Dimitri Miras"
    },
    {
      "affs": [
        2,
        3
      ],
      "name": "Matthias Blüher"
    },
    {
      "affs": [
        4
      ],
      "name": "Pedro Orozco Del Pino"
    },
    {
      "affs": [
        4
      ],
      "name": "Donna Mojdami"
    },
    {
      "affs": [
        4
      ],
      "name": "Rachel L. Batterham"
    },
    {
      "affs": [
        4
      ],
      "name": "Kevin Trice"
    },
    {
      "affs": [
        4
      ],
      "name": "Benjamin Goebel"
    },
    {
      "affs": [
        4
      ],
      "name": "Fatih Tangi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1sj5syqrbec1m.bib",
  "cited_by": 0,
  "doi": "10.1016/j.obpill.2026.100346",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13697276/",
  "id": "1sj5syqrbec1m",
  "issns": [
    "2667-3681"
  ],
  "landing_url": "https://doi.org/10.1016/j.obpill.2026.100346",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Clinical Research/Investigation"
    ],
    [
      "openalex",
      "2736|Pharmacology and Obesity Treatment"
    ]
  ],
  "openalex": "W7221790376",
  "pdf_url": "https://europepmc.org/articles/PMC13697276?pdf=render",
  "pmcid": "PMC13697276",
  "pmid": "42936354",
  "published": "2026-10-14",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/1sj5syqrbec1m.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:21Z",
      "native_id": "PMC13697276",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.obpill.2026.100346"
    },
    {
      "first_seen": "2026-10-30T12:22:12Z",
      "native_id": "MED:42936354",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42936354"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2736|Pharmacology and Obesity Treatment",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial",
  "title_text": "Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:34:20Z",
  "url": "https://research.draconitic.com/paper/1sj5syqrbec1m",
  "venue": "Obesity Pillars",
  "versions": []
}